Last reviewed · How we verify
PLITIDEPSIN
At a glance
| Generic name | PLITIDEPSIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2018 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC) (PHASE2)
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection (PHASE3)
- Extension Study in a Cohort of Adult Patients With COVID-19 Infection (PHASE1,PHASE2)
- Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) (PHASE2)
- Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 (PHASE1)
- Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (PHASE2)
- Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide (PHASE2)
- A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLITIDEPSIN CI brief — competitive landscape report
- PLITIDEPSIN updates RSS · CI watch RSS